分组1 - Nuvation Bio Inc. reported a quarterly loss of $0.11 per share, which aligns with the Zacks Consensus Estimate, showing an improvement from a loss of $0.15 per share a year ago [1] - The company posted revenues of $41.87 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 52.63%, compared to revenues of $5.71 million in the same quarter last year [2] - Nuvation Bio has surpassed consensus revenue estimates four times over the last four quarters, although it has only exceeded consensus EPS estimates once during the same period [2] 分组2 - The stock has underperformed, losing about 34% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is $0.05 on revenues of $48.34 million, and for the current fiscal year, it is -$0.33 on revenues of $197.35 million [7] 分组3 - The Medical - Biomedical and Genetics industry, to which Nuvation Bio belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for Nuvation Bio was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market [6]

Compugen (CGEN) came out with quarterly earnings of $0.6 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to a loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +1,053.85%. A quarter ago, it was expected that this drug developer would post a loss of $0.09 per share when it actually produced a loss of $0.07, delivering a surprise of +22.22%.Over the last four quarters, the company ha ...

Group 1 - Shares of Privia Health (PRVA) have increased by 8.9% over the past four weeks, closing at $24.91, with a mean price target of $31.25 indicating a potential upside of 25.5% [1] - The mean estimate consists of 20 short-term price targets with a standard deviation of $2.99, where the lowest estimate is $23.00 (7.7% decline) and the highest is $37.00 (48.5% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, as indicated by a 1.7% increase in the Zacks Consensus Estimate for the current year [11][12] Group 2 - PRVA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13] - While price targets are often viewed as misleading, the direction indicated by the consensus price target may serve as a useful guide for investors [10][14] - Analysts' price targets can be influenced by business relationships, leading to potentially inflated estimates, but a low standard deviation among targets suggests a consensus on price movement direction [8][9]

Gogo (GOGO) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -166.67%. A quarter ago, it was expected that this in-flight internet provider would post earnings of $0.07 per share when it actually produced earnings of $0.1, delivering a surprise of +42.86%.Over the last four quarters, the company has ...

Amadeus IT Group SA Unsponsored ADR (AMADY) came out with quarterly earnings of $0.84 per share, beating the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.76 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +11.26%. A quarter ago, it was expected that this company would post earnings of $0.94 per share when it actually produced earnings of $0.98, delivering a surprise of +4.26%.Over the last four ...

分组1 - Cable One reported a quarterly loss of $1.35 per share, significantly missing the Zacks Consensus Estimate of $7.6, and down from earnings of $1.53 per share a year ago, resulting in an earnings surprise of -117.76% [1] - The company posted revenues of $363.74 million for the quarter ended December 2025, which was 1.49% below the Zacks Consensus Estimate and a decrease from $387.21 million in the same quarter last year [2] - Over the last four quarters, Cable One has only surpassed consensus EPS estimates once and has also topped consensus revenue estimates just once [2] 分组2 - Cable One shares have declined approximately 19.4% since the beginning of the year, contrasting with the S&P 500's gain of 1.5% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is $7.36 on revenues of $365.87 million, and for the current fiscal year, it is $29.69 on revenues of $1.45 billion [7] 分组3 - The Zacks Industry Rank indicates that the Cable Television industry is currently in the bottom 26% of over 250 Zacks industries, suggesting potential underperformance compared to higher-ranked industries [8] - The estimate revisions trend for Cable One was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6]

PACS Group, Inc. (PACS) came out with quarterly earnings of $0.43 per share, missing the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.25 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -9.47%. A quarter ago, it was expected that this company would post earnings of $0.46 per share when it actually produced earnings of $0.32, delivering a surprise of -30.43%.Over the last four quarters, the compan ...

Core Insights - Strategic Education (STRA) reported quarterly earnings of $1.74 per share, exceeding the Zacks Consensus Estimate of $1.47 per share, and showing an increase from $1.27 per share a year ago, resulting in an earnings surprise of +18.10% [1] - The company achieved revenues of $323.21 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.04% and increasing from $311.46 million year-over-year [2] - Strategic Education has consistently outperformed consensus EPS estimates over the last four quarters, achieving this four times [2] Earnings Outlook - The future performance of Strategic Education's stock will largely depend on management's commentary during the earnings call and the sustainability of the stock's price movement based on recent earnings and future expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $1.40, with expected revenues of $314.78 million, and for the current fiscal year, the EPS estimate is $6.48 on revenues of $1.32 billion [7] Industry Context - The Schools industry, to which Strategic Education belongs, is currently ranked in the top 9% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% of industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]

Natera (NTRA) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of a loss of $0.46 per share. This compares to a loss of $0.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +175.43%. A quarter ago, it was expected that this genetic testing company would post a loss of $0.39 per share when it actually produced a loss of $0.64, delivering a surprise of -64.1%.Over the last four quarters, ...

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to a loss of $1.2 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +53.33%. A quarter ago, it was expected that this company would post a loss of $1.6 per share when it actually produced a loss of $1.16, delivering a surprise of +27.5%.Over the last four quarters, the company has surpasse ...